Profound Medical (NASDAQ:PROF; TSX:PRN) appointed accomplished global medical device industry veteran, Kenneth Knudson, as chief commercial officer to lead Profound’s worldwide sales, marketing and reimbursement activities.
In an executive management career spanning more than 25 years, Mr. Knudson has achieved results ranging from accelerating growth for emerging start-ups to advancing success for Fortune 500 companies.
Most recently, he served as CEO of Perineologic, a company pioneering a new and disruptive approach to prostate cancer biopsy. He also served as EVP of global sales and marketing at Boston Scientific and held the same position at privately-held Augmenix, prior to its 2018 acquisition by Boston Scientific.
Among other accomplishments while at Boston Scientific/Augmenix, Mr. Knudson helped drive annual sales of SpaceOAR Hydrogel from nil to over $100-million in just four years. SpaceOAR Hydrogel, a biodegradable material that is injected between the rectum and prostate, decreases a patient’s exposure to rectal radiation, one of the most common complications of prostate radiotherapy.
Prior to joining Augmenix, Mr. Knudson led the global re-launch strategy for Cheetah Medical’s non-invasive cardiac output monitoring device. And his early career included progressive sales leadership roles with Boston Scientific’s urology and women’s health divisions.
In a statement, Arun Menawat, Profound’s CEO and chairman, said Mr. Knudson’s “extensive and demonstrable record of accomplishment in helping to commercialize new medical technologies in urology, combined with his deep knowledge of the men’s and women’s health markets, will be invaluable as we continue to execute our commercial strategies for TULSA-PRO and Sonalleve.”
Mr. Knudson said he has watched the “scale, scope and speed with which leading urologists and teaching hospitals have already begun to adopt TULSA-PRO, particularly in the U.S. I am incredibly energized by this opportunity to build on that and look forward to being part of the Profound team as we execute the next stages of our growth strategy.”
